Table 1 Patient characteristics of the test group and the validation group
Test group n patients (%) | Validation group n patients (%) | p-value | |
|---|---|---|---|
Age | 0.76 | ||
65-70 years | 230 (41) | 217 (39) | |
71-80 years | 266 (47) | 283 (50) | |
≥ 81 years | 69 (12) | 64 (11) | |
Gender | 0.89 | ||
Female | 197 (35) | 201 (36) | |
Male | 368 (65) | 363 (64) | |
Type of primary tumor | 0.91 | ||
Breast cancer | 89 (16) | 106 (19) | |
Prostate cancer | 150 (27) | 159 (28) | |
Myeloma/lymphoma | 51 (9) | 50 (9) | |
Lung cancer | 112 (20) | 108 (19) | |
Cancer of unknown primary | 44 (8) | 45 (8) | |
Renal cell carcinoma | 34 (6) | 32 (6) | |
Colorectal cancer | 28 (5) | 25 (4) | |
Other tumors | 57 (10) | 39 (7) | |
Number of involved vertebrae | 0.78 | ||
1-2 | 235 (42) | 219 (39) | |
3-4 | 191 (34) | 196 (35) | |
≥ 5 | 139 (25) | 149 (26) | |
Ambulatory status prior to RT | 0.84 | ||
Not Ambulatory | 234 (41) | 228 (40) | |
Ambulatory | 331 (59) | 336 (60) | |
Other bone metastases | 0.99 | ||
No | 229 (41) | 229 (41) | |
Yes | 336 (59) | 335 (59) | |
Visceral metastases | 0.29 | ||
No | 319 (56) | 347 (62) | |
Yes | 246 (44) | 217 (38) | |
Interval from cancer diagnosis to RT of MSCC | 0.67 | ||
≤ 15 months | 290 (51) | 302 (54) | |
> 15 months | 275 (49) | 262 (46) | |
Time developing motor deficits | 0.47 | ||
1-7 days | 175 (31) | 193 (34) | |
8-14 days | 140 (25) | 150 (27) | |
> 14 days | 250 (44) | 221 (39) | |
Radiation regimen | 0.99 | ||
1 × 8 Gy | 96 (17) | 95 (17) | |
5 × 4 Gy | 154 (27) | 157 (28) | |
10 × 3 Gy | 151 (27) | 153 (27) | |
15 × 2.5 Gy | 64 (11) | 67 (12) | |
20 × 2 Gy | 100 (18) | 92 (16) |